Alta Partners, a leading early-stage healthcare investment firm, held the first and final closing of Alta Partners NextGen Fund III, L.P. today. Fund III was oversubscribed and has total capital of $275 million. The Alta team will continue its successful strategy of investing in curative, breakthrough therapeutics and technology-enabled healthcare services.

Alta Partners raised NextGen Fund I in 2017, and Fund II in 2019. Both funds focused on a concentrated portfolio of companies working with an outstanding group of entrepreneurs to make broad impacts on disease and healthcare delivery. In the four years since Fund I was closed, the portfolio of early-stage companies invested in by the fund have grown into over $19 billion in enterprise value.

Alta Partners has invested in some of the leading biotech therapeutics companies, including Allakos, VIR Biotechnology, Be Biopharma, and TYRA Biosciences. “Working with Alta on developing TYRA has not only been incredibly helpful, but I wouldn’t have launched the company without them,” said Todd Harris, CEO. “Alta focuses on a small portfolio of companies and goes all-in to help them succeed.”


Read More

Source: PR Newswire